Paclitaxel and carboplatin combination therapy-induced pure red cell aplasia in endometrial cancer patient and favorable response to low-dose corticosteroid treatment: a case report
This case highlights PRCA as a potential complication of carboplatin-paclitaxel therapy, emphasizing the importance of obtaining reticulocyte counts and bone marrow studies in cases of refractory chemotherapy-induced anemia. Early low-dose corticosteroid intervention proved effective and safe. Clinicians should include PRCA in the differential diagnosis during chemotherapy toxicity surveillance to optimize supportive care in cancer patients.
Authors
- Chengxu Zheng (ORCID: https://orcid.org/0009-0005-7511-1025)
- Meng Chen (ORCID: https://orcid.org/0000-0003-0351-5897)
- Lixiang Yan (ORCID: https://orcid.org/0000-0003-3818-045X)
- Ying Zhang (ORCID: https://orcid.org/0000-0002-7613-6188)
- Zhexin Shi (ORCID: https://orcid.org/0000-0003-2994-426X)
- Jiayu He (ORCID: https://orcid.org/0000-0002-3624-1178)
Institutions
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Chinese Clinical Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/cco-25-32
- Citations
- 1
- Primary Topic
- Chemotherapy-related skin toxicity
- Type
- article
- Field-Weighted Citation Impact
- 2.00